Sales & Marketing

Biopharma to request second look at approval.

Drug expected to support children aged 4 and 5 with Duchenne muscular dystrophy.

Medications expected to improve blood sugar control in children 10 years and older.

Project intends to increase diverse representation in medical imagery.

Medicine created for patients with difficulty swallowing tablets.

Collaboration to focus on identifying clinical development candidates.

Group to be fully integrated into Verix lab.

Initiative to support developing manufacturers launch new products.

Collaboration to focus on personalized medicine in the United Arab Emirates capital.

Pharma giant to absorb oral treatment specialist.

Biopharma aims to strengthen field engagement with healthcare professionals.

Company reportedly on schedule to make drug available in the second half of this year.

Medicine expected to be available immediately via prescription.

Assets include cardiology, otic infections, and pain management.

Research to focus on the treatment of atherosclerotic cardiovascular disease.

Forces pharma giant to hand over marketing communications with Meta.

Expansion expected to create additional production capacity, company says.

Decision based on data collected from patients in the early stages of the disease.

Deal will pay $19 billion to states accusing companies of contributing to the issue.

Deal reached with a potential equity value of $3.5 billion.

With the sales boom from COVID-19 products now in the rear-view, a resetting is underway for those in Pharm Exec’s listing of the top biopharma producers—shifting attention to new Rx roads ahead and the steady strategies needed to navigate a bumpy business terrain.

The new era of generative AI is poised to impact pharma marketing and engagement in powerful and lasting ways. But amid all the technological praise, what are the key considerations brand teams must navigate?

Amid the shifting focus from primary care to specialty care, using data-driven tactics can create tailored campaigns and meaningful relationships with nurse practitioners and physician assistants.

Company raises 2023 net income expectations by an estimated $425 million.

Transaction expected to provide shareholders with immediate value.

Prevymis to focus on disease in high-risk adult kidney transplant recipients.

Creative audacity and innovation often take a backseat to rigid regulatory adherence in pharma advertising—but there are exceptions.

Ryan Mason, Jeffrey D. Erb to join as chief marketing officer and chief media officer, respectively.

DeepIntent OS expected to give publishers access to company’s comprehensive suite.

Israeli pharmaceutical organization expected to evaluate the offer.